We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 19, 2023

Ibrutinib for the First-Line Treatment of Chronic GVHD

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study
J. Clin. Oncol 2023 Jan 06;[EPub Ahead of Print], DB Miklos, M Abu Zaid, JP Cooney, JC Albring, M Flowers, AP Skarbnik, I Yakoub-Agha, BS Ko, B Bruno, EK Waller, J Yared, SK Sohn, CE Bulabois, T Teshima, D Jacobsohn, H Greinix, A Mokatrin, Y Lee, JT Wahlstrom, L Styles, G Socie

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading